Drug intelligence / Profile preview

AMG 378

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

AMG 378 is an investigational small molecule drug developed by Amgen. It is currently in early clinical development, with its mechanism of action not yet disclosed publicly. The drug is being evaluated primarily for the treatment of ulcerative colitis and has also been studied in healthy volunteers to assess safety, tolerability, and pharmacokinetics. As of mid-2025, it remains a new molecular entity with no approved indications or known adverse events reported from trials[4][5][7].

Beyond the preview

Go deeper on AMG 378.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 378.

Explore the full profile